TY - JOUR
T1 - Haploidentical HSCT
T2 - A 15-year experience at San Raffaele
AU - Bonini, C.
AU - Peccatori, J.
AU - Stanghellini, M. T L
AU - Vago, L.
AU - Bondanza, A.
AU - Cieri, N.
AU - Greco, R.
AU - Bernardi, M.
AU - Corti, C.
AU - Oliveira, G.
AU - Zappone, E.
AU - Traversari, C.
AU - Bordignon, C.
AU - Ciceri, F.
PY - 2015/6/6
Y1 - 2015/6/6
N2 - Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant platforms and post transplant cellular-based interventions. We showed that T cell-depleted haploidentical transplantation followed by the infusion of genetically modified donor T cells (TK007 study, Eudract-2005-003587-34) promotes fast and wide immune reconstitution and GvHD control. This approach is currently tested in a phase III multicenter randomized trial (TK008 study, NCT00914628). We targeted patients with advanced leukeia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Results of these approaches are summarized and discussed.
AB - Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant platforms and post transplant cellular-based interventions. We showed that T cell-depleted haploidentical transplantation followed by the infusion of genetically modified donor T cells (TK007 study, Eudract-2005-003587-34) promotes fast and wide immune reconstitution and GvHD control. This approach is currently tested in a phase III multicenter randomized trial (TK008 study, NCT00914628). We targeted patients with advanced leukeia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Results of these approaches are summarized and discussed.
UR - http://www.scopus.com/inward/record.url?scp=84930450747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930450747&partnerID=8YFLogxK
U2 - 10.1038/bmt.2015.99
DO - 10.1038/bmt.2015.99
M3 - Article
C2 - 26039212
AN - SCOPUS:84930450747
VL - 50
SP - S67-S71
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
ER -